Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current treatment for Ewing's sarcoma.

Mihir M Thacker1, H Thomas Temple, Sean P Scully

  • 1Department of Orthopaedics and Rehabilitation, University of Miami School of Medicine (D-27), PO Box 016960, Miami, FL 33101, USA. thackermihirm@yahoo.com

Expert Review of Anticancer Therapy
|May 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term Oncologic Outcomes After Unplanned Soft Tissue Sarcoma Surgery: Implications for Surveillance Strategies.

Clinical orthopaedics and related research·2026
Same author

Team Approach: Diagnosis and Management of Pediatric Pelvic Ewing Sarcoma.

JBJS reviews·2026
Same author

Evaluation and prediction of knee kinematics and kinetics in children with Blount disease.

Gait & posture·2026
Same author

Do Patients Who Undergo Conversion of Failed Osteoarticular Allografts to Megaprostheses Have Worse Outcomes Than Patients Treated With Primary Megaprostheses at Initial Resection?

Clinical orthopaedics and related research·2026
Same author

IlluminOss photodynamic bone stabilization system: Retrospective cohort review of clinical and peri-operative imaging complications.

Clinical imaging·2026
Same author

Effect of Timing of First Consultation with a Sarcoma Specialist Following Unplanned Excision: Oncologic Outcomes of Patients with Soft-Tissue Sarcomas.

The Journal of bone and joint surgery. American volume·2026
Same journal

Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine.

Expert review of anticancer therapy·2026
Same journal

Barriers to the use of brachytherapy for treatment of cervical cancer and prostate cancer in low- and middle-income countries.

Expert review of anticancer therapy·2026
Same journal

The dual role of Schlafen11 in brain tumors: Jekyll and Hyde.

Expert review of anticancer therapy·2026
Same journal

Central nervous system-related permanent consequences in long-term survivors of pediatric Langerhans cell histiocytosis: a clinical overview and monitoring strategies.

Expert review of anticancer therapy·2026
Same journal

RTsDEN: reverse task attention enabled deep learning model for lung cancer detection using computed tomography.

Expert review of anticancer therapy·2026
Same journal

The potential impact of glucagon-like peptide 1 receptor agonists for the treatment of endometrial carcinoma.

Expert review of anticancer therapy·2026
See all related articles

Ewing sarcoma, a group of aggressive bone tumors in children, requires multidisciplinary treatment. Advances in understanding its molecular biology are crucial for developing novel therapies to improve patient outcomes.

Area of Science:

  • Pediatric Oncology
  • Skeletal System Neoplasms
  • Molecular Biology

Background:

  • Ewing sarcoma is the second most common pediatric bone tumor, presenting as a group of related disorders.
  • Characterized by specific chromosomal translocations involving the EWS gene, leading to chimeric oncoproteins.
  • Includes Ewing sarcoma of bone, extra-osseous Ewing sarcoma, Askin tumor, and peripheral neuroectodermal tumor.

Purpose of the Study:

  • To review current treatment modalities for Ewing sarcoma.
  • To highlight recent advancements and novel approaches in managing this condition.

Main Methods:

  • Review of existing literature on Ewing sarcoma treatment.
  • Analysis of recent therapeutic strategies and molecular insights.

Related Experiment Videos

Main Results:

  • Multidisciplinary approaches have improved prognosis, but survival rates remain challenging.
  • 20-40% of localized and 80% of metastatic cases are fatal despite aggressive treatment.

Conclusions:

  • Understanding the molecular basis of Ewing sarcoma is key to developing targeted therapies.
  • Continued research into novel treatment strategies is essential for improving survival rates.